- Research Article
- 10.1097/mop.0000000000000349
Editorial introductions
- Apr 01, 2016
- Current Opinion in Pediatrics
Editorial introductions
Current Opinion in Pediatrics was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of pediatrics are divided into 18 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editor and Section Editors for this issue. EDITOR Philip A. PizzoPhilip A. PizzoPhilip A. Pizzo, MD, is the David and Susan Heckerman Professor and Founding Director of the Stanford Distinguished Careers Institute, USA. Dr Pizzo served as Dean of the Stanford School of Medicine from April 2001 to December 2012, where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Dr Pizzo has devoted much of his distinguished medical career to the diagnosis, management, prevention and treatment of childhood cancers and the infectious complications that occur in children whose immune systems are compromised by cancer and AIDS. He has also been a leader in academic medicine, championing programs and policies to improve the future of science, education and healthcare in the US and beyond. Dr Pizzo received his MD degree with Honors and Distinction in Research from the University of Rochester, USA in 1970, and completed an internship and residency at Children's Hospital Medical Center in Boston, USA, a teaching fellowship at Harvard Medical School, USA, and a clinical and research fellowship in pediatric oncology at the National Cancer Institute. Pizzo served as Head of the Institute's Infectious Disease Section, Chief of the NCI's Pediatric Department, and Acting Scientific Director for NCI's Division of Clinical Sciences between 1973 and 1996. Before joining Stanford in 2001, he was the Physician-in-Chief of Children's Hospital in Boston and Chair of the Department of Pediatrics at Harvard Medical School, where he was also the Thomas Morgan Rotch Professor of Pediatrics. Dr Pizzo is the author of more than 615 scientific articles and 16 books and monographs, including Principles and Practice of Pediatric Oncology, the Seventh Edition of which was published in 2015. He co-led a multidisciplinary committee for the Institute of Medicine (IOM) that resulted in the 2011 report Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research; he also co-chaired the IOM report Dying in America: Improving Quality and Honoring Individual Preferences at the End of Life, which was published in 2015. Dr Pizzo has received numerous awards and honors, among them the Public Health Service Outstanding Service Medal in 1995, the Barbara Bohen Pfiefer Award for Scientific Excellence in 1991, the Elizabeth Kubler-Ross Award in 2008, the Ronald McDonald Charities Award of Excellence in 2009, and the John and Emma Bonica Public Service Award in 2013. He is the 2012 recipient of the John Howland Award, the highest honor for lifetime achievement bestowed by the American Pediatric Society. He has been elected to a number of prestigious organizations and societies, including the Association of American Physicians, the American Society of Clinical Investigation, the American Pediatric Society and the Institute of Medicine of the National Academy of Sciences, where he was also elected to the Governing Council. The IOM became the National Academy of Medicine in 2015. Dr Pizzo has served as Chair of the Association of Academic Health Centers, and Chair of the Council of Deans of the Association of American Medical Colleges, and was elected to the Board of Directors of the American Society for Clinical Oncology and the Infectious Diseases Society of America. He was President of the International Immunocompromised Host Society (1998–2011). He served on the Governing Board for the California Institute of Regenerative Medicine from 2004–2012. In 2009 he was elected to the Board of Trustees of the University of Rochester and the Board of Overseers of Koc University in Istanbul, Turkey. He is also a member of the Board of Directors of MRI Interventions and the Academic Advisory Council for Merritt Hawkins. In 2014 he was elected to the Board of Directors of the Ludwig Institute for Cancer Research and in 2015 he was elected to the Board of Directors of Global Blood Therapeutics. SECTION EDITORS Susan M. BlaneySusan M. BlaneySusan M. Blaney, MD, is a Professor and Executive Vice Chair for the Department of Pediatrics at Baylor College of Medicine, USA and the Director of Texas Children's Cancer Center at Texas Children's Hospital, USA. She is a board-certified pediatric oncologist whose career over the past 25 years has focused on the development of new agents and therapeutic strategies for children with recurrent or refractory cancer, particularly for those with malignancies of the central nervous system. She has extensive experience in clinical translational research and currently serves as the Vice Chair for the Children's Oncology Group (COG), an NCI-funded cooperative effort of 200 leading children's hospitals across North America. Dr Blaney has played a leadership role in the development of numerous early phase clinical trials of novel agents for the treatment of childhood cancer over the course of her career. Dr Blaney has also served as a mentor to many pediatric medical students, residents, fellows and faculty who are current or developing leaders in the field of pediatric oncology. Her influence in the field also extends to numerous advisory roles that she has held including an service on the National Cancer Institute's Clinical Trial Advisory Committee, as a member of the Investigational Drug Steering Committee for the National Cancer Institute, as a regular consultant for the FDA's Pediatric Oncology Drug Advisory Committee, as well as for other leading cancer organizations such as the American Association for Cancer Research and the American Society of Clinical Oncology. She also directs or has served on the scientific advisory boards for many not-for-profit foundations for childhood cancer research. Dr Blaney has published more than 200 articles in peer-reviewed journals, has authored numerous book chapters, and is an editor for Rudolph's Pediatrics as well as an Associate editor for Pizzo and Poplack's Principles and Practice of Pediatric Oncology, the leading textbook in the field of pediatric oncology. Daniel W. GreenDaniel W. GreenDr Daniel W. Green has been practicing at the Hospital for Special Surgery, USA since 1998 and is currently the Director of the Pediatric Sports Program for the Division of Pediatric Orthopedic Surgery. While he thoroughly enjoys caring for patients from birth into early adulthood, he has a special interest in pediatric sports injuries and pediatric knee injuries, in addition to pediatric orthopedic trauma. He provides emergency treatment for pediatric fractures and other orthopedic emergencies at New York Presbyterian Hospital-Manhattan, USA and the Hospital for Special Surgery. His focus is to provide the finest, most advanced orthopedic care available and is devoted to advancing treatments in order to improve patient outcomes and the overall patient experience. His research focuses on pediatric knee surgery, cartilage repair and restoration, pediatric ACL surgery, pediatric growth plate surgery, pediatric fracture care, and osteogenesis imperfecta. He has extensively studied the surgical options for patellar dislocations, evaluating both conservative and surgical approaches to stabilizing the patella. He has also investigated surgical techniques for ACL reconstruction in the skeletally immature. Dr Green is a clinical professor of orthopedic surgery at the Weill Cornell Medical College, USA. Yvonne J. BrysonYvonne J. BrysonDr Yvonne J. Bryson is a Distinguished Professor and recent past Chief of Global Pediatrics Infectious Diseases at David Geffen School of Medicine at UCLA, Mattel Children's, USA. She is a world-renowned leader, researcher, virologist and clinician in the field of HIV pathogenesis, prevention, and treatment of maternal-fetal and pediatric HIV-1, and is an active member of the HIV CURE Scientific Committee of International Maternal Pediatric and Adolescent AIDS Clinical trials network (IMPAACT) and the Adolescent trials network for identification and treatment of HIV acute infection. She is past Chair of the NIH Network IMPAACT PMTCT Committee (Prevention of Mother-to-Child Transmission of HIV) as well as a previous past chair. She has served a national and international leadership role for the past 25 years in studies of prevention and treatment of pediatric HIV. She has served on the HIV Therapeutics Trans NIH panel to set the NIH agenda for the past eleven years. Dr Bryson was influential in the development of CDC and Public Health guidelines for the diagnosis and treatment of HIV-infected pregnant women and has been involved in the planning and execution of national cooperative studies of maternal-fetal HIV transmission. She has made significant contributions to the development of the original studies of the use of Zidovudine and Nevirapine for the prevention of perinatal HIV. She published studies of maternal risk factors for vertical transmission of HIV including viral load and autologous neutralizing antibody, as well as advances in the early diagnosis of HIV in newborns. Her research at UCLA has been funded by NIH for over twenty-five years. She has over 190 original peer-reviewed publications and is a sought-after lecturer and reviewer. She was founding advisor and one of the original health board advisors of the Elizabeth Glaser Pediatric AIDS Foundation, with co-founders Elizabeth Glazer, Susie Zeegan and Susan Delorentis, and colleagues Dr Richard Stiehm and Phil Pizzo. She participated and helped plan the EGPAF thinktanks, the Ariel Project, the Elizabeth Glazer Scientist Award, and fundraising strategies for the foundation and the role of NIH in promoting new investigators in the field. She also was involved in political activism in Washington DC and California with Elizabeth and cofounders to focus attention on children. Dr Bryson has served on numerous NIH study section reviews and panels. She had significant experience in global health issues related to reduction of maternal infant mortality and morbidity and meeting the millennium goals. Dr Bryson has had significant leadership and field experience setting up NIH funded clinical trials, laboratories and infrastructure in Brazil over the past 13 years. She has trained a large number of students and post-doctoral MD, PhD scholars and junior faculty who are now national and international leaders as academic faculty or public health professionals in the US and around the world. Dr Bryson is a strong advocate for mothers and children for the prevention and treatment of infectious disease and is now committed to the CURE for HIV. She still has active NIH RO1 grants for studies of HIV remission and cure in infants and children, collaboration on an infant maque monkey model, and most recently, studies in adolescents in Los Angeles and New Orleans. She is an expert in perinatal infections, pediatric infectious disease, antivirals herpes infections, and other viral, bacterial, and opportunistic infections, and serves as a pediatric infectious disease consultant. Henry H. BernsteinHenry H. BernsteinDr Bernstein is a Professor of Pediatrics at Hofstra Northwell School of Medicine in New York, USA. He taps into his extensive 32-year experience as a general pediatrician in private practice and in academia at urban, suburban, and rural children's hospitals to promote the health and wellbeing of children, their families, and their communities. His private, community-based primary care (generalist) experiences in combination with academic experiences have provided him with a value-added, translational science perspective, unique from many others in academia. This tacit knowledge enables him to fulfill a lifelong passion of communicating, educating, and translating science into clinical settings, educational venues, policy-making, and media interactions to advance the health of children. Research is consistently woven into the fabric of Dr Bernstein's clinical practice, which has served as a “laboratory” for his active studies. His research and quality improvement initiatives focus on issues important to Academic General Pediatrics and community-based practice, including immunizations, postpartum newborn discharge, childhood obesity, breastfeeding, health promotion, preventive health screening in primary care, technology, and medical education. His commitment, innovative spirit, and enthusiasm also encompass many facets of medical education along the continuum, from training and mentoring future physicians to fostering lifelong learning, to supporting the continuous professional development of practicing pediatricians. Hank is an ex-officio member of the American Academy of Pediatrics’ Committee on Infectious Diseases (Red Book Committee), Associate Editor of Red Book Online, and AAP liaison to the CDC Advisory Committee on Immunization Practices’ Influenza Workgroup, spearheading both seasonal and pandemic influenza preparedness and policy for children. In addition, he is Editor-in-Chief Emeritus of PediaLink, the AAP's online home for lifelong learning and chair of the interdisciplinary Bright Futures Health Promotion Workgroup, which has created a distinctive health promotion curriculum, videos, and a companion educational website (www.pediatricsinpractice.org). He regularly shares his knowledge and expertise by educating the public, writing for health information websites, and participating in media interviews on a variety of pediatric health care issues including immunization, diagnosis and treatment of common childhood infectious diseases and illnesses, and practical information for parents, teachers and caregivers. In the spirit of lifelong learning, Hank earned a masters in healthcare management at Harvard School of Public Health, USA, in 2013. He actively maintains his certification by the American Board of Pediatrics. He completed his residency training in pediatrics at St Christopher's Hospital for Children in Philadelphia, USA, after earning his medical degree from the University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine, USA. Hank and his wife, Sophie, have been married for 36 years and are extremely proud of their 31-year-old daughter, Lauren, and 26-year-old son, David.
Editorial introductions
Editorial introductions
Editorial introductions
Editorial introductions
Editorial introductions
Editorial introductions
Building better oncology data systems and workforce models in a rapidly changing health care system.
Building better oncology data systems and workforce models in a rapidly changing health care system.
Abstract 908: Development of a cell proliferation assay to be used as a read-out system for determining the in vivo potency of bevacizumab in neutralizing the biological activity of VEGF in cancer patients
INTRODUCTION: Blocking of vascular endothelial growth factor (VEGF) by the monoclonal antibody bevacizumab or by VEGF-Trap is a validated clinical approach to block tumor angiogenesis. For these anti-angiogenic therapeutics there is still a major lack of knowledge on biological determinants that are predictive for clinical benefit in cancer patients. We reasoned that a test that would assess the inhibition of the biological activity of VEGF by bevacizumab in the patients’ plasma or serum during therapy would serve as a biomarker for response. We tested such an approach by measuring the inhibition of VEGF-dependent cell proliferation by patients’ serum using the Ba/F3-R2 cell line, which is a murine pre-B lymphocyte cell line stably transfected with a fusion protein, consisting of the extracellular domain of hVEGFR2 and the transmembrane and cytoplasmic domain of the mouse erythropoietin receptor. When grown in medium devoid of mIL-3, this cell line is solely dependent on VEGF for proliferation and survival. METHODS: Ba/F3-R2 cells (licensed by the Ludwig Institute for Cancer Research, New York, NY) were seeded at a density of 200.000 cells/mL and cultured for 72 hours in the presence of either A)medium containing hVEGF pre-incubated for 1 hour with various concentrations of bevacizumab (Avastin, Roche /Genentech) or B) naïve serum or serum ( 5 or 10%) collected after one cycle of bevacizumab from 7 patients with metastatic colorectal cancer that was pre-incubated with VEGF. Serum VEGF concentrations of these patients were previously determined by ELISA Cell proliferation was subsequently quantified with the cell proliferation agent WST-1 (Roche). RESULTS: The optimal VEGF concentration to study bevacizumab-mediated modulation of VEGF dose-dependent proliferation of Ba/F3-R2 cells was 1.25 ng/ml. At this concentration, Ba/F3-R2 cell proliferation was inhibited for 50-80% using a clinically effective bevacizumab concentration of 10 μg/mL. Co-incubation of VEGF with naïve serum samples did not have any inhibitory effect on Ba/F3-R2 cell proliferation, while 30-90% inhibition of Ba/F3-R2 cell proliferation was observed when VEGF was co-incubated with serum of 7 patients who had received one cycle of bevacizumab treatment. Furthermore, a significant negative correlation (R2 = 0.85, p = 0.0030) was found between free -VEGF concentrations in serum after one cycle of treatment with bevacizumab and proliferation inhibition of Ba/F3-R2 cells. CONCLUSIONS: We have developed an assay that can be used to reproducibly determine the efficacy of bevacizumab in neutralizing the biological activity of VEGF both in vitro and in patient-derived serum samples before and during treatment with bevacizumab. We propose that this assay could serve as a potential biomarker to predict response to bevacizumab and possibly other agents that target VEGF. Citation Format: Madelon Q. Wentink, Henk J. Broxterman, Tanja D. de Gruijl, Roberto Pili, Hans J. van der Vliet, Arjan W. Griffioen, Henk M.W. Verheul. Development of a cell proliferation assay to be used as a read-out system for determining the in vivo potency of bevacizumab in neutralizing the biological activity of VEGF in cancer patients. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 908. doi:10.1158/1538-7445.AM2014-908
Read moreAbstract 2498: The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies
The modified vaccinia strain Ankara (MVA) is attenuated and non-propagative but retains infectivity and immunogenicity, its large DNA genome allows the insertion of several full-length coding sequences for disease associated antigens or other transgenes of interest. MVA based targeted immunotherapeutics are designed to induce a cytolytic cellular immune response. TG4010 expresses the full-length sequences of MUC1 and IL2 and was tested in combination with first line platin-based chemotherapy in stage IV non-small cell lung cancer (NSCLC) versus chemotherapy alone (NCT00415818 and NCT01383148); 108 plaque forming units (pfu) was given S/C weekly for 6 weeks then every three weeks up to progression. TG4001 expressing E6 and E7 of HPV16, and IL2 was assessed versus placebo in women with cervical intra-epithelial neoplasia (CIN2/3) (NCT01022346) at the dose of 5.107 pfu, three S/C injections a week apart. TG4040 expresses the HCV antigens NS3, NS4 and NS5B and was evaluated in combination with peg-interferon-α and ribavirin versus the same treatment alone in treatment-naïve patients with chronic hepatitis C, (107 pfu). Two distinct schedules of administration were evaluated: with or without immunotherapy run-in phase (NCT01055821). A total of 729 patients were included and randomized in these four studies: 443 in active arms (185 NSCLC, 136 CIN2/3, 122 HCV) and 286 in control arms. In all studies the repeated S/C administration of the MVA vectors alone or in combination therapies appeared feasible and well tolerated, neither dose reduction nor modification of the schedules of administration have been necessary. Injection site reactions have been the most frequent adverse events associated with treatment, mild to moderate in the majority of cases. Despite lower doses they seemed more prevalent for vectors expressing xenoantigens (TG4001 99% pts, TG4040 42% pts) than for TG4010 (31%). The phase II studies with TG4010 met their primary endpoints based respectively on 6 month progression free survival (PFS) and overall PFS. The primary endpoint of improvedcomplete early viral response (cEVR) was also achieved in the study with TG4040. These studies had in common 1/ to combine the MVA from the beginning of standard of care and 2/ to use a schedule of administration with a run-in phase of 6 or more weekly injections followed by at least monthly injections. The study with TG4001 did not meet its threshold-based primary endpoint of complete response but significantly more women in the experimental arm had a clearance of their cervical lesions at a conization performed 6 months later. Three MVA-based immunotherapeutics have shown meaningful clinical activity in different settings. Their favorable safety profile allows the combination of these products with standard of care therapies and also with immune checkpoint inhibitors (ongoing). Citation Format: Jean-Marc LIMACHER, Elisabeth QUOIX, Heiner WEDEMEYER, Francisco GARCIA, Pekka NIEMINEN, Gisèle LACOSTE, Delphine AGATHON, Geraldine HONNET, Elizabeth CALLEJA, Isabelle DIDILLON, Berangère MARIE-BASTIEN. The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2498. doi:10.1158/1538-7445.AM2015-2498
Read moreAcademic, Leadership, and Demographic Characteristics of Orthopaedic Sports Medicine Division Chiefs in the United States
Introduction:Division chiefs (DCs) play an integral role within the department, making critical decisions and helping shape the future of both the division and the department. This study aimed to investigate the demographic characteristics and scholarly work of DCs in academic orthopaedic sports medicine division in the United States.Methods:Orthopaedic residency programs at academic centers were identified using the Association of American Medical Colleges' Electronic Residency Application Service. DCs were identified using the program's respective websites where data points such as sex, race/ethnicity, fellowship training institution, time since graduating fellowship, academic rank, number of degrees, and additional leadership titles were collected. Scopus database was used to determine h-indices.Results:From the 191 programs identified, 100 had a DC for the sports medicine subspecialty division, and 66 programs offered a sports medicine fellowship. Most DCs (96%) were men. The racial/ethnic demographics of the DCs were mostly White (86%), followed by Asian (11%), African American (1%), Hispanic/Latino (1%), and mixed ethnicity (1%). On average, the DCs were 19.6 years past their fellowship completion. The average h-index was 21.2. Many (48%) had an academic rank of professor, 28% associate professor, and 12% assistant professor. Four held additional graduate degrees. The fellowship programs that trained the most DCs were Hospital for Special Surgery (11), Kerlan Jobe Orthopaedic Clinic (8), University of Pittsburgh (7), American Sports Medicine Institution (5), Cleveland Clinic (5), Cincinnati Sports Medicine (4), Massachusetts General Hospital (4), and Steadman Hawkins Clinic (4).Discussion:DCs in academic orthopaedic surgery plays a crucial role in the department and is a topic that is understudied. A lack of diversity exists among DCs in academic Sports Medicine in orthopaedics. The position is held predominately by White men with a rank of either full or associate professor and extensive leadership experience. More efforts are needed to increase the diversity of sports medicine leadership within academic orthopaedic programs in the United States.
Read moreEditorial introductions.
Editorial introductions.